

Session Title: #73: Molecular Profiling in Breast Cancer: Ten Years Later

Session Type: Education Session

Date: Friday, June 4

Location: E Hall D1

Time: 4:30 PM - 5:45 PM

- The Past and The Future of Molecular Profiling
Charles M. Perou, PhD
 - Do Other Clinically Relevant Subtypes Exist?
Richard Iggo, MD, PhD
 - How to integrate molecular profiling with standard pathology in clinical practice
George W. Sledge, MD
-

Session Title: #103: Therapeutic Options for Patients with Breast Cancer with a Family History or BRCA Mutation

Session Type: Education Session

Date: Saturday, June 5

Location: E Arie Crown Theater

Time: 8:00 AM - 9:15 AM

- Surgical options for breast cancer patients with a BRCA 1/2 mutation or a familial predisposition
Marian B.E. Menke-Pluymers, MD, PhD
- Radiation therapy and hereditary breast cancer
Abram Recht, MD
- Systemic therapy in BRCA1 and BRCA2 mutation carriers with breast cancer
Susan M. Domchek, MD

Session Title: #268: Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

Session Type: Special Session

Date: Saturday, June 5

Location: N Hall B1

Time: 9:30 AM - 12:00 PM

- Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

Daniel D. Von Hoff, MD

Session Title: #112: Clinical Management of Hereditary Colorectal Cancer

Session Type: Meet the Professor Session

Date: Saturday, June 5

Location: E451b

Time: 3:00 PM - 4:15 PM

- Clinical Management of Hereditary Colorectal Cancer

Randall Burt, MD

Session Title: #37: Cutaneous Cancer Syndromes

Session Type: Education Session

Date: Saturday, June 5

Location: E353

Time: 4:45 PM - 6:00 PM

- Overview of cutaneous cancer syndromes

Sancy Ann Leachman, MD

- Melanoma genetics and risk assessment

Hensin Tsao, MD

- Advances in Cowden's Syndrome

Stephen B. Gruber, MD, PhD

Session Title: #167: Highlights of the Day I including Clinical Trials Participation Awards

- Highlights of the Day I including Clinical Trials Participation Awards
Everett E. Vokes, MD
 - Clinical Trials Participation Awards
Douglas W. Blayney, MD
 - Discussion: Lymphoma and Plasma Cell Disorders
Bruce D. Cheson, MD
 - Discussion: Lung Cancer - Local/Regional and Adjuvant Therapy
Alan B Sandler, MD
 - Discussion: Patient and Survivor Care
Gretchen Genevieve Kimmick, MD
 - Discussion: Melanoma/Skin Cancers
F. Stephen Hodj, MD
-

Session Title: #44: Evaluating the Evidence and Marketing of Pharmacogenomic Tests

Session Type: Education Session

Date: Sunday, June 6

Location: E353

Time: 11:30 AM - 12:45 PM

- Overview of pharmacogenomics: history, development and role in FDA labeling
Howard L. McLeod, PharmD
 - Cyp2D6 testing and tamoxifen
Matthew P. Goetz, MD
 - Clinical cases in pharmacogenomics
Michael L. Maitland, MD, PhD
-

Session Title: #143: Plenary Session including Science of Oncology Award and Lecture

Session Type: Plenary Session

Date: Sunday, June 6

Location: N Hall B1

Time: 1:00 PM - 4:00 PM

- Plenary Session including Science of Oncology Award and Lecture
Douglas W. Blayney, MD
- Plenary Session including Science of Oncology Award and Lecture
Daniel F. Hayes, MD
- Plenary Session including Science of Oncology Award and Lecture
Frank McCormick, PhD, FRS
- #LBA1-Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or Fallopian tube cancer (FTC): A Gynecologic Oncology Group study.

Robert A Burger

- Discussion
Elizabeth A. Eisenhauer, MD
- #2-Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC).
Elisabeth A. Quoix
- #3-Clinical activity of the oral ALK inhibitor, PF-02341066, in ALK-positive patients with non-small cell lung cancer (NSCLC).

Yung-Jue Bang

- Discussion
Martin J. Edelman, MD
- #4-A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma.

Steven O'Day, MD

- Discussion: Ipilimumab: The light at the end of the tunnel?

Vernon K Sondak, MD

Session Title: #99: The Evolution of a Disease: How Does the Changing Epidemiology of Esophagogastric Cancers Affect Treatment Decisions?

Session Type: Education Session

Date: Sunday, June 6

Location: E Hall D1

Time: 4:45 PM - 6:00 PM

- Understanding the evolution in epidemiology of esophago-gastric cancer.

Johanna C. Bendell, MD

- The molecular continuum of Barrett's esophagus to esophagogastric cancer.

Jason L Hornick, MD, PhD

- Using the newest molecular markers in prognosis and risk stratification.

Janusz Jankowski, PsyD

Session Title: #168: Highlights of the Day II including Partners in Progress Award

Session Type: Highlights of the Day

Date: Monday, June 7

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day II including Partners in Progress Award

Kim Allyson Margolin, MD

- Highlights of the Day II including Partners in Progress Award

Douglas W. Blayney, MD

- Partners in Progress Award Recipient

Ellen V. Sigal, PhD

- Discussion: Genitourinary (Prostate) Cancer

Nicholas J. Vogelzang, MD

- Discussion: Gastrointestinal (Colorectal) Cancer

Howard S. Hochster, MD

- Discussion: Gynecologic Cancer

Claire F. Verschraegen, MD

- Discussion: Myeloma

Jean L. Harousseau, MD

- Discussion: Cancer Prevention/Epidemiology

Scott Michael Lippman, MD

Session Title: #79: From the Cancer Genome to Patients with Cancer: The Next Generation of Innovation - An ASCO/AACR Joint Session

Session Type: Special Session

Date: Monday, June 7

Location: S404

Time: 4:45 PM - 6:00 PM

- Welcome and Introduction
Douglas W. Blayney, MD
- Next generation sequencing and clinical applications
Stephen B. Gruber, MD, PhD
- System Medicine in Cancer Therapeutics
Jeffrey M. Trent, PhD
- Challenges in Clinical Tumor Genotyping Applications
A. John Iafrate, MD, PhD
- Conclusion
Tyler Jacks, PhD

Session Title: #124: Advances in Hereditary Pancreatic Cancer

Session Type: Clinical Problems in Oncology Session

Date: Monday, June 7

Location: E451a

Time: 4:45 PM - 6:00 PM

- Pancreatic cancer screening
Teresa Brentnall, MD
- Genetics of hereditary pancreatic cancer
Ralph Hruban, MD
- Surgical management of hereditary pancreatic cancer
Sean J. Mulvihill, MD

Session Title: #169: Highlights of the Day III

Session Type: Highlights of the Day

Date: Tuesday, June 8

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Discussion: Breast Cancer - Local/Regional and Adjuvant Therapy
Kathy Miller, MD
- Discussion: Lung Cancer - Metastatic
Charles M. Rudin, MD, PhD
- Discussion: Sarcoma
Gary K. Schwartz, MD
- Discussion: Gastrointestinal (Noncolorectal) Cancer
C. D. Blanke, MD
- Discussion: Head and Neck Cancer
Everett E. Vokes, MD